[,] GLP-1 receptor agonists are currently classified as Food and Drug Administration (FDA) pregnancy category C, indicating that while animal studies have shown adverse fetal effects, adequate and well-controlled studies in pregnant women are deficient, and these agents are not recommended for use during pregnancy
2017, www.ncbi.nlm.nih.gov/pmc/articles/PMC5549431/, Pizzorno, Joseph
the in vivo and clinical literature is substantially less developed
Ischemic stroke was obtained from MEGASTROKE consortium (34,217 cases and 406,111 controls) [25], the UK Biobank (7961 cases and 384,003 controls), and Finngen Biobank (10,551 cases and 208,241 controls) [26]
Researchers identified several factors including heart failure, type 2 diabetes, substance abuse, anticoagulant use and hypertension that contributed to much of the individualized treatment effect for kidney cancer risk
Switching from retatrutide to cagrilintide is somewhat simpler because you are moving from a broader mechanism to a narrower one